Search Results - "Gogat Marchant, Karin"

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial by Lambert, Juliette, Pautas, Cécile, Terré, Christine, Raffoux, Emmanuel, Turlure, Pascal, Caillot, Denis, Legrand, Ollivier, Thomas, Xavier, Gardin, Claude, Gogat-Marchant, Karïn, Rubin, Stephen D, Benner, Rebecca J, Bousset, Pierre, Preudhomme, Claude, Chevret, Sylvie, Dombret, Herve, Castaigne, Sylvie

“…The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy…”
Get full text

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia by Gambacorti‐Passerini, Carlo, Cortes, Jorge E., Lipton, Jeff H., Dmoszynska, Anna, Wong, Raymond S., Rossiev, Victor, Pavlov, Dmitri, Gogat Marchant, Karin, Duvillié, Ladan, Khattry, Navin, Kantarjian, Hagop M., Brümmendorf, Tim H.

“…Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical activity and acceptable tolerability in chronic phase chronic myeloid…”
Get full text

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33 Positive Acute Myeloid Leukemia: Results from a French Retrospective Observational Study by Lambert, Juliette, Raffoux, Emmanuel, Lebon, Delphine, Braun, Thorsten, Heiblig, Mael, Santagostino, Alberto, Gogat-Marchant, Karin, Pautas, Cécile

“…Introduction: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate targeting CD33 with a calicheamicin derivative payload. GO is approved in France in…”
Get full text